ImpediMed (IPD) Q2 2026 earnings summary

Executive summary

• Achieved record quarterly revenue of AUD 3.9 million ($3.9 million), up 8% sequentially and 18% year-on-year, with annual recurring revenue (ARR) at AUD 14.4 million ($14.4 million), a 15% increase year-over-year.

• 57 SOZO units sold globally in Q2, with 19 in the US and 38 internationally; global installed base now at 1,166 units.

• Reimbursement coverage for BCRL reached 92.8% nationally, covering 323 million US lives, up from 87% in Q1.

• Cash balance at quarter end was AUD 18.9 million ($18.9 million), providing 6.5 quarters of operating runway at current burn rate.

• SOZO Pro launched, with FDA clearance for a new bilateral lymphedema algorithm and new 510(k) filed for expanded body composition offering.

Financial highlights

• Quarterly revenue reached a record AUD 3.9 million ($3.9 million), up 18% year-on-year and 8% sequentially.

• Cash outflow improved to AUD 2.9 million ($2.9 million) from AUD 5.6 million ($5.9 million) in the previous quarter.

• Cash receipts from customers rebounded to AUD 3.8 million ($3.8 million), up 12% quarter-on-quarter.

• Staff costs increased to AUD 5.3 million ($5.3 million) due to redundancy payments.

• Total contract value (TCV) for the quarter was AUD 4.1 million ($4.1 million), down from AUD 4.7 million ($4.7 million) in Q1.

Outlook and guidance

• Over 700 sales opportunities in the pipeline, with plans to attend 19 conferences in H2 FY26 to build awareness and drive sales.

• Focus on expanding reimbursement coverage, targeting 100% for BCRL, and leveraging new SOZO Pro product launch.

• Commercial pilots for Heart Health in the US are underway, with initial sales on track and CPT code reimbursement available.

• Wellness and Weight Management market entry initiated, targeting a $220 million addressable market and over 30,000 sites of care identified.

• Ongoing cost control measures and staff reductions to support path to cash flow break-even.